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Clinics and pathology 
Disease 
Juvenile myelomonocytic leukemia. 
 
Morphology of JMML. Bone marrow smears were stained with 
May-Grünwald-Giemsa and shown at 1000-fold magnification. 
Bd=band, Bl=myelomonoblast Eb=erythroblast, Mc=myelocyte, 
Mo=monocyte, Pm=promyelocyte, Se=segmented neutrophylic 
granulocyte. 
Epidemiology 
So far 1 case known. 
Evolution 
At relapse: 45,XY,-4,t(4;17)(q12;q21), 
add(5)(p15),del(7)(q22), -9, -16, -17, 
+3mar[19]/46,XY[5] 
Prognosis 







Partial GTG-banded karyotype of t(4;17)(q12;q21). 
 
FISH analysis using probe LSI RARA DC resulting in a fusion 
signal on chromosome 17 band q21, with a split 5'RARA red 
signal on der(17) and a 3'RARA green signal on der(4) (left 
panel). FISH analysis narrowing the 4q12 breakpoint to the 
proximity of FIP1L1 by using 4q12 specific BAC probes RP11-
120K16/RP11-317M1 with a fusion signal on chromosome 4 
band q12, with RP11-120K16 hybridizing to der(4)(green) and 
RP11-317M1 hybridizing to der(17)(red) (right panel). 
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FIP1L1: Conserved FIP domain; RARA; DBD DNA binding domain, LBD ligand binding domain. 
Variants 
In APL 17q21 RARA frequent rearrangement in: 
t(15;17)(q22;q21), fused with PML; in related 
translocations, rarely observed, involve a common 
breakpoint in 17q21, within RARA, fused with 
different partners, in: t(11;17)(q23;q21), fusion with 
PLZF, t(5;17)(q35;q12), fusion with NPM1, in 
t(11;17)(q13;q21), fusion with NUMA and in 
dup(17)(q12q21), fusion with Stat5b. In 
myeloproliferative disease CEL 4q12 FIP1L1 
rearrangement: fusion to PDGFRA due to 800 kb 
interstitial deletion. 




FIP1L1 is a subunit of the cleavage and 
polyadenylation specific factor (CPSF) complex that 
binds to U-rich elements via arginine-rich RNA 





Wide expression; nuclear receptor; binds specific DNA 
sequences: HRE (hormone response elements); ligand 
and dimerization domain; role in growth and 
differentiation. 




In-frame fusion of exon 15 of FIP1L1 to exon 3 of 
RARA 
Transcript 
5' FIP1L1 - 3' RARA and 5' RARA - 3' FIP1L1 
Fusion protein 
Description 
The fusion mRNA would encode a 832 amino acids 
FIP1L1/RARA chimeric protein containing the 428 
amino-terminal amino acids of FIP1L, including the 
FIP homology domain and 403 carboxyl-terminal 
amino acids of RARA, including the DNA and ligand 
binding domains, with replacement of FIP1L1 amino 
acid 429 (Valine) and RARA amino acid 60 
(Threonine) into an Alanine. 
Oncogenesis 
All known chimeric RARA fusion proteins provide 
additional homodimerization motifs, promoting 
formation of chimeric homodimers and thereby 
removing requirement of RXR for RARA to bind 
DNA. The homodimerization ability of RARA fusion 
proteins is critical for leukemic transformation. 
Recently, it was shown in a murine system that 
retroviral transduced FIP1L1/PDGFRA mediated 
transformation in vitro and in vivo, is FIP1L1 
independent and results from disruption of the 
autoinhibitory JM domain of PDGFRA. However, 
observations using retroviral transduced 
FIP1L1/PDGFRA and FIP1L1/PDGFRA with an N-
terminal deletion of the FIP1L1 moiety showed 
differences with respect to cytokine-independent 
colony formation and activation of multiple signalling 
pathways in human primary hematopoietic precursor 
cells, indicating that FIP1L1 contributes to 
FIP1L1/PDGFRA resulting in a myeloproliferative 
phenotype. Therefore the function of the FIP1L1 
moiety remains to be resolved. 
To be noted 
We report on reciprocal FIP1L1/RARA fusion 
transcripts resulting from a novel t(4;17)(q12;q21) in a 
case of juvenile myelomonocytic leukemia (JMML). 
JMML is a pediatric myeloproliferative disease (MPD), 
characterized by proliferation of granulocytic and 
monocytic lineages. 17q12 RARA was demonstrated to 
be involved in t(15;17)(q22;q21), resulting in a 
PML/RARA fusion transcript. PML/RARA t(15;17) is 
the hallmark of acute promyelocytic leukemia (APL), 
characterized by a differentiation arrest of abnormal 
promyelocytes. Variant rearrangements involving 
17q21 RARA in APL and APL-like (APL-L) disease 
are PLZF/RARA t(11;17)(q23;q21), NPM1/RARA 
t(5;17)(q35;q21), NUMA/RARA t(11;17)(q13;q21), 
STAT5b/RARA der(17) and t(3;17)(p25;q21). 4q12 
FIP1L1 is fused to PDGFRA as a result of a 
del(4)(q12q12) in myeproliferative disorder CEL. 
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